Navigation Links
Largest Civil Settlement in Pharmaceutical Case Announced by U.S. Department of Justice
Date:4/27/2010

Sheller, P.C. is Primary Counsel for Record-Breaking $520 Million Civil Settlement; Firm Instrumental in Recovering More Than $4.2 Billion in Pharma Settlements in the Last 15 Months

PHILADELPHIA, April 27 /PRNewswire-USNewswire/ -- AstraZeneca will pay the federal government $520 million in civil fines to settle charges of off-label marketing of the powerful antipsychotic drug Seroquel. The settlement is the largest pharmaceutical civil settlement and among the top five civil and criminal drug company settlements in U.S. history.

The first complaint in the matter was filed on behalf of a whistleblower by qui tam whistleblower, class action, and mass tort attorney Stephen A. Sheller, Esq. of Philadelphia's Sheller, P.C. in 2004.

Sheller and firm partner Brian J. McCormick, Jr., Esq. also represented whistleblowers in previous off-label, failure to warn, and consumer fraud drug investigations, including 2009's Eli Lilly and Pfizer record settlements for $1.4 and $2.3 billion respectively. The Sheller firm has been counsel for whistleblowers in cases that have brought more than $4.2 billion in settlements for the United States government in just the last 15 months.

Sheller is also known for pursuing Phillip Morris for fraud in the $10.1 million "light" tobacco verdict and is currently mounting a nationwide consumer class action against Toyota.

Seroquel is approved by the U.S. Food and Drug Administration ("FDA") only for schizophrenia and specific types of bipolar mania. AstraZeneca was charged with promoting Seroquel to physicians for use "off-label" in children and the elderly.  Doctors are allowed to prescribe drugs for unapproved uses but FDA rules state that drug manufacturers may only promote their products for approved conditions and age groups.

The settlement unsealed today by the U.S. Department of Justice and the U.S. Attorney's Office in Philadelphia indicates marketing practices for Seroquel included promotion of the drug by physicians participating in clinical studies and drug sales representatives encouraging doctors to prescribe for the unapproved uses.

Whistleblowers are protected by the federal False Claims Act, where employees aware of their company knowingly defrauding the government may sue without threat of being fired, harassed, demoted, or discriminated against for cooperating in an investigation of their employer.

"My client showed courage and determination in bringing forth the allegations against AstraZeneca," said Sheller. "As a company employee, he knew alerting the government to the marketing practices potentially put his professional life in jeopardy but he believed protecting public safety and bringing attention to fraud against the government outweighed his personal interests."

Sheller lauded the team in the U.S. Attorney's office for their investigation, including Chief of the Civil Division Virginia Gibson and Assistant U.S. Attorney Colin Cherico. "Once again, the U.S. Attorney's office in Philadelphia came through, supporting whistleblower efforts, recouping hundreds of millions for the government and its citizen taxpayers," said Sheller.

Seroquel is among the top-selling drugs in the world with 2009 sales of $4.9 billion, 15% of AstraZeneca's $33.2 billion in revenue.

About Sheller, P.C.

Sheller P.C. (http://www.Sheller.com) is among the preeminent plaintiff and qui tam whistleblower law firms in the United States. Stephen A. Sheller, Esq., Managing Partner, has been an effective advocate for victims for nearly three decades. Sheller is currently representing large, multi-state classes of Toyota owners nationwide and has litigated groundbreaking cases ranging from tobacco fraud, defective drugs, products liability and whistleblower lawsuits. The firm also practices in complex mass tort and commercial litigation involving business disputes and consumer fraud. Known as the leader of the "Charge of the 'Light Brigade'" Sheller won a $10.1 million verdict against Phillip Morris for consumer fraud in the marketing of "light" cigarettes.  Sheller also initiated the Palm Beach County, Florida litigation involving the 2000 U.S. Presidential election and the "butterfly ballots" which launched him into national media prominence as a lead attorney challenging the voting count. Sheller is frequently interviewed by national media and appears on "The American Law Journal," the television talk program on the law that airs on the Philadelphia CNN-affiliate.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Stephen A. Sheller, Esq.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=85992

Brian J. McCormick, Jr., Esq.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=94931


'/>"/>
SOURCE Sheller, P.C.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
3. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
4. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
5. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. Universite de Montreal Researchers Simulate Worlds Largest Heart Model Using SGI Technology
8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
9. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
10. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
11. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
Breaking Medicine News(10 mins):